In vivo pharmacokinetics and tissue distribution profile of a Wnt/β-catenin pathway-targeting anticancer cassane diterpene isolated from Caesalpinia pulcherrima
Sandani De Vass Gunawardane, Epitawala Arachchige Oshadi, Shalini K. WijerathneiD, P. A. Nimal PunyasiriiD, Arumugam Murugananthan, Sameera R. SamarakooniD, Kanishka Sithira SenathilakeiD
Abstract
A cassane diterpene, 6{beta}-cinnamoyl-7-hydroxyvouacapen-5-ol (6{beta}CHV), isolated from Caesalpinia pulcherrima, has emerged as a promising anticancer drug lead with reported Wnt/{beta}-catenin pathway inhibitory activity and in vivo safety. The present study reports the in vivo pharmacokinetics and tissue distribution of 6{beta}CHV in Wistar rats following a single oral dose of 200 mg/kg. A reproducible RP-HPLC-UV method was developed and validated for quantifying 6{beta}CHV in rat plasma and tissues. Chromatographic separation was achieved using a gradient elution of methanol and water. The method was subsequently applied to investigate the pharmacokinetics and tissue distribution of 6{beta}CHV. Plasma pharmacokinetic analysis revealed delayed and moderate absorption, with a Tmax of 4 h and a Cmax of 1314.12 ng/mL. Following absorption, 6{beta}CHV is distributed widely across peripheral tissues, including the liver, heart, lungs, spleen, and kidneys, as well as pharmacological sanctuary sites such as the brain and testes. The highest concentrations were observed in the stomach, small intestine, and liver, with detectable levels persisting up to 24 h, reflecting extensive tissue partitioning and retention. Overall, these findings demonstrate that oral administration of 6{beta}CHV is feasible. However, the delayed absorption suggests that further optimization of formulation or alternative administration routes may enhance systemic exposure. This study provides the first comprehensive pharmacokinetic and tissue distribution profile of 6{beta}CHV, supporting its continued preclinical development as a potential anticancer therapeutic. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=125 SRC="FIGDIR/small/715187v1_ufig1.gif" ALT="Figure 1"> View larger version (18K): org.highwire.dtl.DTLVardef@1621f86org.highwire.dtl.DTLVardef@1039b3aorg.highwire.dtl.DTLVardef@1c40175org.highwire.dtl.DTLVardef@13bcf2f_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A network pharmacology-based approach and molecular docking study to explore the therapeutic potential of a nutraceutical formula (Vernolac) in the treatment of cancer
Sandani De Vass Gunawardane, Matheen Muhammadh Milhan, … Sameera R. Samarakoon·PLoS ONEPeer-reviewed·Jul 1, 2026
- In vitro anti-cancer properties of a commercially available polyherbal nutraceutical (Vernolac) capsule on cancer stem cell-like (NTERA-2 cl.D1) cells.
Poorni Chanuka Rathnayake, Duvinika Chalani Senavirathna, … Sameera R. Samarakoon·Egyptian Journal of Basic and Applied SciencesPeer-reviewed·Dec 2, 2025
- Differential Induction of Cancer Cell Death by Root, Leaf, and Flower Extracts derived from Kalanchoe pinnata
Mitsuki Maedomari, Sakura Kawada, Nanae Harashima·bioRxiv·May 30, 2026
- Preclinical efficacy and safety of Tegavivint in Wnt-activated hepatocellular carcinoma
Toshiyasu Suzuki, Ciara Curran, … Thomas Graham Bird·bioRxiv·Jul 16, 2026
- Antinociceptive properties of an oral formulation of Δ9-tetrahydrocannabinol in aqueous 2-hydroxypropyl-β-cyclodextrin in female rats
Farshid Bagheri, María Scherma, … Fabrizio Sanna·bioRxiv·Aug 10, 2026
- Inhibitory Properties of Cannabis sativa Seed Extract on Pancreatic Cancer Cells
Fatemeh Salah, Mohammad Masoudi, … Sadrollah Ramezani·bioRxiv·Jul 27, 2025